Big pharma earnings preview: what to expect from GSK and AstraZeneca Q1 results
Britain’s two largest drug makers both unveil their first quarter results on Wednesday, with investors eager to an update on how the Covid-19 crisis impacted the pairs performance.
GlaxoSmithKline (GSK) and AstraZeneca both unveil their first quarter (Q1) results on Wednesday, with investors keen to see the impact of the Covid-19 crisis on their financial performance.
AstraZeneca is looking to increase its total revenue by a ‘high single-digit to a low double-digit percentage’ and its core earnings per share (EPS) is forecast to increase by a ‘mid- to high-teens percentage’, according to its previous guidance.
GSK is expecting adjusted EPS to decline by -1% to -4% CER and is targeting a dividend pay-out of 80p per share in 2020.
Investors will be interested to see the impact of the coronavirus on both drug markers performance over their first three months of trading, though most companies guidance this year is heavily weighted towards the latter half of 2020.
GSK: technical analysis
Shares in GSK have been on a rip of late, with the market valuation gaining 28% since the March lows. The question from here is whether we can sustain this uptrend, as the stock pushes towards the prior peak of £18.25, according to Josh Mahony, senior market analyst at IG.
The short-term outlook will be dictated by the reaction to this confluence of resistance, with the ascending trendline and 76.4% Fibonacci resistance level meeting around £17.08. A break through this inflection point could bring about a bullish continuation signal.
However, given the existence of this current bearish rising wedge pattern, we could see some downside come into play if this zone of resistance is not broken. In particular, if we break below £16.43, things could start taking a more significant bearish turn.
AstraZeneca: technical analysis
AstraZeneca shares have experienced an incredible 41% upside since the March low, with the stock hitting a record high for three-weeks in a row.
This wider weekly chart highlights how significant this move has been, with a standard deviation channel indicating that things could be a little stretched at these levels.
For now we have not seen any bearish intraday signals, yet it could be prudent to be aware of a potential pullback if the short-term picture starts to sour somewhat.
How to trade stocks with IG
Looking to trade GSK and other stocks? Open a live or demo account with IG and buy (long) or sell (short) the asset using derivatives like CFDs in a few easy steps:
Create an IG trading account or log in to your existing account
Enter ‘GlaxoSmithKline’ in the search bar and select it
Choose your position size
Click on ‘buy’ or ‘sell’ in the deal ticket
Confirm the trade
This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.
Act on stock opportunities today
Go long or short on thousands of international stocks with CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
- Forex
- Shares
- Indices
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.
